Objective To investigate the clinical efficacy and related mechanism of Shexiang Tongxin Dropping Pill combined with conventional therapy in patients with myocardial ischemia reperfusion injury (MIRI).

Methods A total of 96 acute myocardial infarction (AMI) patients with MIRI after percutaneous coronary intervention (PCI) were selected as study objects, and were randomly divided into combined group and conventional group, with 48 cases per group. On the basis of conventional group, Shexiang Tongxin Dropping Pills were added to the combined group, and both groups were treated for 1 month. The indicators of cardiac function and cardiomyopathological remodeling, serum myocardial injury markers, inflammation indicators and efficacy before and after treatment were compared.

Results The effective rate in the combined group was 97.83%, which was higher than 87.50% in the conventional group (P < 0.05); the left ventricular end diastolic diameter (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular ejection fraction (LVEF), stroke volume (SV), serum creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-ProBNP) were improved in both groups compared with those before treatment, and the combined group had more improvement than the conventional group (P < 0.05); the serum levels of nod-like receptor protein 3 (NLRP3) inflammasome, hypersensitive C-reactive protein (hs-CRP) and interleukin-1β (IL-1β) in the two groups were decreased after treatment, and the combined group decreased more significantly than the conventional group (P < 0.05).

Conclusion Shexiang Tongxin Dropping Pill combined with conventional treatment can relieve persistent myocardial injury, improve cardiac function and cardiomyopathological remodeling in patients with MIRI, and the therapeutic effect is superior to western medicine alone.